The BSPAR Etanercept registry, established in 2004, collects detailed information on the effectiveness and safety of Etanercept in children with JIA. A parallel group of children with JIA treated with Methotrexate is also being recruited in order to compare side effects and long term outcomes between the two treatment groups. The study, previously known as the Biologics and New Drugs Register (BNRD), moved to The University of Manchester to sit among the other national rheumatic disease biologic registers. Discussions about extending the recruitment period are currently underway.

The lead investigator is: Dr. Kimme Hyrich - University of Manchester
Website: www.aruk.manchester.ac.uk/bspar/